Literature DB >> 28829863

Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.

Dhruv S Kazi1, Joanne Penko2, Pamela G Coxson2, Andrew E Moran3, Daniel A Ollendorf4, Jeffrey A Tice5, Kirsten Bibbins-Domingo5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28829863      PMCID： PMC5817484          DOI： 10.1001/jama.2017.9924

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  2 in total

1.  Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Authors:  Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo
Journal:  JAMA       Date:  2016-08-16       Impact factor: 56.272

2.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

Authors:  Marc S Sabatine; Robert P Giugliano; Anthony C Keech; Narimon Honarpour; Stephen D Wiviott; Sabina A Murphy; Julia F Kuder; Huei Wang; Thomas Liu; Scott M Wasserman; Peter S Sever; Terje R Pedersen
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245
  2 in total
  41 in total

Review 1.  Are PCSK9 Inhibitors Cost Effective?

Authors:  Max J Korman; Kjetil Retterstøl; Ivar Sønbø Kristiansen; Torbjørn Wisløff
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 2.  Cost-Effectiveness and Challenges of Implementing Intensive Blood Pressure Goals and Team-Based Care.

Authors:  Catherine G Derington; Jordan B King; Kelsey B Bryant; Blake T McGee; Andrew E Moran; William S Weintraub; Brandon K Bellows; Adam P Bress
Journal:  Curr Hypertens Rep       Date:  2019-11-07       Impact factor: 5.369

Review 3.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

4.  Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.

Authors:  BinBin Zheng-Lin; Alberto Ortiz
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

5.  Cell-associated heparin-like molecules modulate the ability of LDL to regulate PCSK9 uptake.

Authors:  Adri M Galvan; John S Chorba
Journal:  J Lipid Res       Date:  2018-11-21       Impact factor: 5.922

6.  Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.

Authors:  Paul L Hess; Kevin Kennedy; Michael Cowherd; Salim S Virani; Frederick A Masoudi; Ann Marie Navar; Robert W Yeh; P Michael Ho; Thomas M Maddox
Journal:  Am Heart J       Date:  2017-09-09       Impact factor: 4.749

7.  Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events.

Authors:  Thomas S G Sehested; Jenny Bjerre; Seul Ku; Andrew Chang; Alison Jahansouz; Douglas K Owens; Mark A Hlatky; Jeremy D Goldhaber-Fiebert
Journal:  JAMA Cardiol       Date:  2019-02-01       Impact factor: 14.676

8.  Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.

Authors:  Marc S Sabatine; Stephen D Wiviott; KyungAh Im; Sabina A Murphy; Robert P Giugliano
Journal:  JAMA Cardiol       Date:  2018-09-01       Impact factor: 14.676

9.  Application of PCSK9 Inhibitors in Practice.

Authors:  Tina M Kaufman; Bruce A Warden; Jessica Minnier; Joshua R Miles; P Barton Duell; Jonathan Q Purnell; Cezary Wojcik; Sergio Fazio; Michael D Shapiro
Journal:  Circ Res       Date:  2019-01-04       Impact factor: 17.367

10.  Diabetes: Anti-PCSK9 antibodies - beneficial or inducers of diabetes?

Authors:  Rutger Verbeek; G Kees Hovingh
Journal:  Nat Rev Endocrinol       Date:  2017-11-09       Impact factor: 43.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.